Berkshire Exits UNH Entirely; Margin Repair Thesis Still Unproven

What happened

Berkshire Hathaway has sold its entire UnitedHealth stake, removing a high-profile long-term holder and amplifying skepticism around UNH's margin-repair story. The company's Q1 MCR improvement to 83.9% was predominantly due to favorable reserve development, while utilization and unit costs remain elevated, according to the 10-Q. Medicare Advantage funding still trails forward trends, forcing management to accept membership contraction as a deliberate margin-defense strategy. The operating thesis for UNH relies on future quarters proving that pricing discipline and cost controls can sustainably improve underwriting margins. Until that evidence emerges, the Berkshire exit reinforces the wait-and-see stance but does not fundamentally change the investment calculus.

Implication

For holders, the sale adds sentiment pressure but does not alter the fundamental gate: only Q2 and Q3 2026 results—showing MCR at or below 84% driven by current-period trends—can validate the thesis. New buyers should wait for that proof, as valuation at 29x earnings is not cheap given unresolved regulatory tail risks (RADV, DOJ) and persistent medical cost headwinds. The attractive entry at $340 offers a margin of safety if headwinds intensify, but near-term catalyst risk is elevated. The bear scenario (MCR above 85%) remains plausible and would push the stock below $280. Prudent investors should remain on the sidelines until operating evidence, not sentiment, clarifies the trajectory.

Thesis delta

The Berkshire Hathaway divestiture removes a high-conviction shareholder and adds a modest negative signal, but it does not shift our thesis because our rating was already WAIT based on unproven margin repair. The key checkpoints remain Q2 and Q3 2026 MCR disclosures, not Berkshire's portfolio moves. Confidence in the thesis is unchanged—still contingent on operating evidence rather than investor sentiment.